Biotech · Private company · Fort Worth, TX, US
AyuVis Research, Inc.
Track this companyFree. Adds AyuVis Research, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- AVR-48Phase 1 · Safety IssuesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Single Ascending Dose and Multiple Ascending Dose Study of AVR-48PHASE1 · NOT_YET_RECRUITING · started Jun 1, 2025ClinicalTrials.gov NCT06847698 · fetched Nov 12, 2026
NIH awards4
- Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonatesFiscal year 2026 · $359.8KNIH RePORTER 5R44HD112276-03 · fetched Nov 12, 2026
- Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonatesFiscal year 2025 · $712.5KNIH RePORTER 5R44HD112276-02 · fetched Nov 12, 2026
- Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonatesFiscal year 2024 · $895.4KNIH RePORTER 1R44HD112276-01A1 · fetched Nov 12, 2026
- Phase-1 Healthy adult human safety and pharmacokinetic study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in at-risk pre-term infantsFiscal year 2024 · $279.8KNIH RePORTER 5R61HL164372-02 · fetched Nov 12, 2026